Drugs targeting PI3K/Akt activity are currently in clinical trials, however, CRC patients exhibit some resistance to these drugs.7–10 In addition, as inappropriate activation of the Wnt/β-catenin pathway was first linked to CRC, there is an intense interest in developing effective inhibitors.11 Unfortunately, the activation or inhibition of a single signaling pathway is unlikely to result in a substantial improvement in disease progression given the co-activation of numerous oncogenic pathways in this cancer. This evidence concerns the gene PIK3CA and colorectal carcinoma.